Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancer.

Autor: Zhang T; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Wei Y; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Hong BH; Division of Medical Sciences, National Cancer Centre Singapore, Singapore., Sumiyoshi T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan., Ong EHW; Division of Medical Sciences, National Cancer Centre Singapore, Singapore., Zeng H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Li Y; Department of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Ng CF; Department of Surgery, and SH Ho Urology Center, Chinese University of Hong Kong, Hong Kong, Hong Kong., Pan J; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Fang B; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Wang B; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Wu J; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Wang H; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Akamatsu S; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.; Department of Urology, Nagoya University Graduate School of Medicine, Aichi, Japan., Chua MLK; Division of Medical Sciences, National Cancer Centre Singapore, Singapore.; Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.; Oncology Academic Programme, Duke-NUS Medical School, Singapore., Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China., Zhu Y; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Shanghai Genitourinary Cancer Institute, Shanghai, China.
Jazyk: angličtina
Zdroj: Clinical and translational medicine [Clin Transl Med] 2023 Sep; Vol. 13 (9), pp. e1411.
DOI: 10.1002/ctm2.1411
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje